Growing AI Collaboration SLP’s recent partnerships with NVIDIA and collaborations with the U.S. FDA and Lonza highlight a focus on AI-driven, GPU-accelerated drug development workflows. This indicates strong potential to sell advanced AI and high-performance computing solutions to their expanding biopharma and healthcare client base.

Educational Expansion The successful global rollout of the 2026 Spring School, attracting over 1,400 scientists, demonstrates SLP’s commitment to expanding expertise in model-informed drug development. This creates opportunities to upsell training, consulting, and implementation services to organizations seeking to build in-house capabilities.

Tech-Enabled Learning Platform SLP’s platform integrates open source LMS with Google technology, appealing to organizations looking for simplified, familiar, and scalable training solutions. There is potential to expand sales by offering customized integrations, premium features, or bespoke training packages.

Market Positioning With a revenue range between 50 million and 100 million and a focus on AI and simulation, SLP is well-positioned to attract enterprise clients across biotech, pharma, and healthcare sectors. Targeted outreach to R&D and clinical development departments could drive new software and service sales.

Industry and Competition SLP’s focus on AI-assisted drug development aligns with market trends toward digital transformation in healthcare. Differentiating offerings around AI integration, simulation capabilities, and professional training can help capture market share from competitors with similar technological expertise.